labs
Master Lab Trends
Lab Trends — Master Tracker
Key Markers at a Glance
| Marker | Most Recent | Date | Trend | Normal Range | Page |
|---|---|---|---|---|---|
| Hemoglobin | 12.0 g/dL | 2026-05-27 | FIRST NORMAL since AML diagnosis (was 9.9 May 17 nadir) | 12.0–15.0 g/dL | Hemoglobin |
| WBC | 2400 /cumm | 2026-05-27 | Leukopenia deepening — NADIR (was 3500 May 23, 4600 May 17) | 4000–10000 /cumm | Wbc |
| ANC | 1460 /cumm | 2026-05-27 | MODERATE NEUTROPENIA — NADIR (below 1500 threshold) | 2000–7000 /cumm | Anc |
| Platelets | 107 K | 2026-05-27 | Stabilizing in 103-117K range (nadir May 11: 103K) | 150–400 K | Platelet Count |
| RBC | 3.77 M/cumm | 2026-05-27 | Recovering (+0.60 from May 17 nadir 3.17) | 3.80–4.80 M/cumm | Rbc Count |
| Sodium | 137 mmol/L | 2026-05-27 | Normal (stable, resolved since May 4) | 136–145 mmol/L | Sodium |
| ESR | 40 mm/hr | 2026-02-20 | Improving (from 130) | 0–35 mm/hr | Esr |
| CRP | 13.8 mg/L | 2025-11-19 | Elevated | <5 mg/L | Crp |
| HbA1c | 5.7% | 2026-03-02 | Unreliable (spuriously low) | <5.7% | Hba1C |
| Fructosamine | 310 µmol/L | 2026-04-22 | HIGH — poor glucose control | 122–236 | Fructosamine |
Additional Markers (Single/Few Data Points)
| Marker | Most Recent | Date | Flag | Normal Range | Page |
|---|---|---|---|---|---|
| MCV | 95.0 fL | 2026-05-27 | H (persistent macrocytosis, stable) | 82–92 (KIMS) | Mcv |
| RDW | 17.8% | 2026-05-27 | H (persistent anisocytosis, slight improvement) | 11.6–13.7% | Rdw |
| Reticulocyte | 1.6% | 2025-11-19 | N (inappropriately normal) | 0.5–2.5% | Reticulocyte Count |
| ANA | 2.2 ratio | 2025-11-19 | Positive | <1.0 | Ana |
| Anti-dsDNA | 29.1 IU/mL | 2025-11-19 | Negative | <100 | Anti Dsdna |
| Anti-CCP | <7.00 U/mL | 2025-11-19 | Negative | ≤17 | Anti Ccp |
| Complement C3 | 140.0 mg/dL | 2025-11-19 | N | 90–180 | Complement C3 |
| Complement C4 | 39.3 mg/dL | 2025-11-19 | N (upper end) | 10–40 | Complement C4 |
| Ceruloplasmin | 29.10 mg/dL | 2025-11-19 | N | 16–45 | Ceruloplasmin |
| Copper, serum | 124.5 ug/dL | 2025-11-19 | N | 80–155 | Copper Serum |
| SPEP | No M-spike | 2025-11-19 | Inflammatory pattern | — | Spep |
| Free Light Chains | K 36.81 / L 26.73 | 2025-11-19 | K:H, L:H, Ratio:N | K 3.3–19.4; L 5.71–26.3 | Free Light Chains |
| Chloride | 98 mmol/L | 2026-05-27 | N (lower limit, normalized — was hypochloremic through Apr 2026) | 98–107 | Chloride |
| Potassium | 4.4 mmol/L | 2026-05-27 | N (stable throughout treatment) | 3.50–5.10 | Potassium |
| Bicarbonate | 28 mmol/L | 2026-05-27 | N (near upper limit; was borderline H 29.5 on May 23) | 22–29 | Bicarbonate |
| Calcium | 9.9 mg/dL | 2026-03-02 | N (was H 10.7 Jan 19, resolved by Jan 22) | 8.60–10.20 | Calcium |
| Creatinine | 0.6 mg/dL | 2026-04-06 | N (stable, range 0.6–0.9) | 0.60–1.20 | Creatinine |
| Magnesium | 1.4 mg/dL | 2026-04-27 | L (improved from 1.2 Apr 20, still below normal) | 1.60–2.60 | Magnesium |
| LFT (ALT/AST/ALP) | 11/15/63 U/L | 2026-04-06 | N (all normal, 3 panels) | 10–35/10–35/35–104 | Lft |
| Lipid Panel | TC 173, LDL 98, HDL 62.6 | 2026-03-02 | N (optimal) | — | Lipid Panel |
| Urea/BUN | 13.4 mg/dL (BUN) | 2026-04-06 | N | 8–23 (BUN) | Urea |
| Folic Acid | >20 ng/ml | 2025-11-17 | N (above range) | 3.10–17.50 | Folic Acid |
| Transferrin | 1.86 g/L | 2025-11-17 | L (chronic disease) | 2–3.60 | Iron Profile |
| TSAT | 16.5% | 2025-11-17 | N | 15–45% | Iron Profile |
| D-Dimer | 0.48 ug/mL | 2022-09-20 | N | <0.5 | D Dimer |
| Total IgE | 134.4 IU/mL | 2022-09-27 | H | ≤100 | Total Ige |
Summary
The lab profile reflects an ongoing AML treatment course (Azacitidine-Venetoclax). Key patterns as of 2026-05-27:
- Hematologic — landmark recovery + active neutropenia nadir: Hemoglobin 12.0 g/dL (FIRST NORMAL since AML diagnosis). RBC recovering (3.77, approaching normal). Platelets stabilizing in 103-117K range (thrombocytopenic but stable). WBC 2400 (leukopenia), ANC 1460 (moderate neutropenia) — WBC/ANC NADIR active. Infection risk elevated. Lineage cascade May 2026: Plt nadir May 11 → Hb nadir May 17 (9.9) → WBC/ANC nadir May 27 (1460). Classic Aza-Ven dissociated lineage kinetics confirmed repeatedly.
- Electrolytes stable/normal: Sodium consistently normal since May 4 (range 137-142). Chloride normalized (98-103, was persistently low 93-96 Mar-Apr 2026). Potassium consistently normal. Bicarbonate normal with occasional borderline high (29.5 on May 23). No Mg result since May 11 (1.5 mg/dL, L).
- Inflammatory markers: ESR improving (130 to 40) with treatment. CRP last checked Nov 2025 -- consider rechecking.
- Metabolic: HbA1c appeared to improve from diabetic (6.8%) to pre-diabetic range (5.7%), but fructosamine 310 µmol/L (HIGH) on Apr 22, 2026 contradicts this. HbA1c unreliable due to altered RBC turnover from AML treatment. True diabetes likely persists with poor control. See Fructosamine, Diabetes Mellitus.
- Autoimmune workup (Nov 2025): ANA positive (2.2) but Anti-dsDNA negative, Anti-CCP negative, complements normal — effectively ruled out SLE and RA as causes of pancytopenia. See Positive Ana.
- Myeloma workup (Nov 2025): SPEP showed inflammatory pattern with no M-spike. Free light chains polyclonally elevated (normal kappa/lambda ratio). Monoclonal gammopathy ruled out. See Spep, Free Light Chains.
- Copper metabolism (Nov 2025): Ceruloplasmin and serum copper both normal — Wilson's disease ruled out. See Ceruloplasmin, Copper Serum.
- Electrolyte panel: Potassium (14 data points) and bicarbonate (13 data points) consistently normal. Chloride (16 data points) persistently low (tracks with sodium). Pattern supports dilutional/SIADH etiology. See Potassium, Bicarbonate, Chloride.
- Liver function (Jan, Mar & Apr 2026): Three LFT panels — all entirely normal. ALT 11–14, AST 15–19, ALP 60–77, bilirubin normal, albumin 4.4 g/dL. No hepatotoxicity despite venetoclax + azacitidine + posaconazole. See Lft.
- Magnesium (Mar, Apr 2026): 1.4 (Mar 2) → 1.2 (Apr 20, nadir) → 1.4 (Apr 27, improving). Still below normal. Supplementation resumption likely. See Magnesium, Magnesium Oral.
- Calcium trend: 10.20 (Jul 2025, N) → 10.7 (Jan 2026, HIGH) → 9.9 (Mar 2026, N). Transient mild hypercalcemia resolved. See Calcium.
- Renal function: Creatinine stable: 0.62 → 0.8 → 0.7 → 0.6 mg/dL across Jul 2025 – Apr 2026. Normal throughout treatment. See Creatinine.
- Lipids (Jul 2025 and Mar 2026): Two panels, both optimal. TC 165→173, LDL 75→98, HDL 69→62.6. Mildly worsened but still well within normal limits. See Lipid Panel.
- Anemia workup (Nov 2025): Folic acid >20 (normal), transferrin 1.86 g/L (low), TSAT 16.5% (normal) — classic anemia of chronic disease pattern. Iron deficiency and folate deficiency ruled out. See Folic Acid, Iron Profile.
- Pre-AML baseline (Sep 2022): Acute inflammatory episode with CRP 128, ESR 119, WBC 14.8K. D-Dimer normal (no thrombosis). IgE elevated (allergic/parasitic component). Resolved within 1 week (CRP normalized, ESR improved). Referred by Sudheendra Ghosh.